slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
235,651-235,680 of 319,975
10
The table uses blue highlighting to emphasize the higher severity metrics in the EBO Ph 2 group.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
11
LSM = Least squares mean. PRO = Patient-Reported Outcome. The slide highlights alignment with FDA guidance for primary endpoints in NTM trials.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
12
The chart highlights a statistically significant improvement (p=0.036) at month 6.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Voice Of Customer1 hit
13
The chart shows a longitudinal comparison of two treatment groups over 6 months. The p-value of 0.043 indicates nominal statistical significance for the difference in mean change from baseline.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · TractionLoop · Voice Of Customer1 hit
14
The slide presents TEAE (Treatment-emergent adverse events) and SAE (Serious adverse events) data.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Traction1 hit
15
Focuses on PRO (Patient Reported Outcomes) as a primary endpoint for the EBO-301 trial.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
16
The slide presents three line charts (A, B, C) comparing PBS, IMI (Imipenem), and two doses of EBO (EBO25, EBO50) over 4 weeks.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
17
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
18
Includes a map showing global distribution and a specific callout for US endemicity.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
19
The slide uses a central hub-and-spoke style diagram to connect funding sources with market potential.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
20
The chart shows Log10 CFU counts in lungs for various treatment groups compared to untreated control.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
21
The slide uses a dual-track timeline approach to show the progression from observational data collection to clinical trial phases.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
22
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
23
Includes a disease progression timeline diagram on the right.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
24
The slide uses a hub-and-spoke diagram to show the global burden relative to specific regions.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
25
The slide uses a dot map to visualize geographic distribution of infections.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
26
Includes chemical structure of the benzoxaborole molecule.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
27
The chart demonstrates superior efficacy of the lead compound over existing treatments (Benznidazole and E1224) in a model that mirrors human clinical outcomes.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
28
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
29
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
30
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
31
The slide uses a hub-and-spoke diagram to connect Boron to various medical fields, with a specific callout to oncology applications.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
32
The slide uses a hub-and-spoke diagram to connect the central Boron element to four therapeutic areas, then links to specific development programs.AN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
33
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Team1 hit
34
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations Beat · Team1 hit
35
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
36
AN2 Therapeutics | Investor Presentation Deck | 36 slidesAN2 Therapeutics | Investor Presentation Deck | 36 slides · AN2 Therapeutics
Pitch deck Investor relations 1 hit
01
AstraZeneca | Results Presentation Deck | 42 slidesAstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Attention1 hit
02
AstraZeneca | Results Presentation Deck | 42 slidesAstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Attention1 hit
03
AstraZeneca | Results Presentation Deck | 42 slidesAstraZeneca | Results Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Attention1 hit